| Basics |
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. It aims to discover small molecule drugs to address Parkinson's, Alzheimer's and schizophrenia.
|
| IPO Date: |
June 1, 2004 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$4.64B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.44 | 2.66%
|
| Avg Daily Range (30 D): |
$0.50 | 2.17%
|
| Avg Daily Range (90 D): |
$0.42 | 1.81%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.2M |
| Avg Daily Volume (30 D): |
1.29M |
| Avg Daily Volume (90 D): |
1.55M |
| Trade Size |
| Avg Trade Size (Sh.): |
128 |
| Avg Trade Size (Sh.) (30 D): |
63 |
| Avg Trade Size (Sh.) (90 D): |
69 |
| Institutional Trades |
| Total Inst.Trades: |
10,060 |
| Avg Inst. Trade: |
$2.3M |
| Avg Inst. Trade (30 D): |
$3.06M |
| Avg Inst. Trade (90 D): |
$3.48M |
| Avg Inst. Trade Volume: |
.1M |
| Avg Inst. Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.18M |
| Avg Closing Trade (30 D): |
$6.06M |
| Avg Closing Trade (90 D): |
$7.36M |
| Avg Closing Volume: |
174.12K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$.43
|
$.16
|
|
Diluted EPS
|
|
$.42
|
$.16
|
|
Revenue
|
$
|
$ 278.63M
|
$ 264.57M
|
|
Gross Profit
|
$
|
$ 256.99M
|
$ 243.83M
|
|
Net Income / Loss
|
$
|
$ 71.78M
|
$ 26.67M
|
|
Operating Income / Loss
|
$
|
$ 35.76M
|
$ 32.37M
|
|
Cost of Revenue
|
$
|
$ 21.65M
|
$ 20.73M
|
|
Net Cash Flow
|
$
|
$ 4.36M
|
$ 36.62M
|
|
PE Ratio
|
|
|
|
|
|
|
